-
2 weeks ago | 
endocrinenews.endocrine.org | Derek Bagley
A new study from the Avon Longitudinal Study of Parents and Children (ALSPAC) is challenging long-held assumptions about how we measure overweight and obesity in children. According to findings published in Obesity and Endocrinology in January 2025, body mass index (BMI) — the most commonly used tool for assessing weight status — may dramatically overestimate overweight prevalence in children when compared with a more nuanced measure: waist-to-height ratio (WHtR).
-
3 weeks ago | 
endocrinenews.endocrine.org | Derek Bagley
Salivary cortisol and cortisone can be valuable tools in diagnosing adrenal insufficiency (AI), offering non-invasive options for screening and potentially avoiding the need for ACTH stimulation tests in some cases, states a recent study in The Journal of Clinical Endocrinology and Metabolism. Adrenal insufficiency (AI), such as in cases of Addison’s disease and Congenital Adrenal Hyperplasia, is a potentially serious condition characterized by inadequate cortisol production.
-
3 weeks ago | 
endocrinenews.endocrine.org | Derek Bagley
Endocrine-disrupting chemicals are everywhere, and there is seemingly no escape. Polychlorinated biphenyls (PCBs) – previously used in a variety of commercial and industrial applications – have been banned for decades but are still found in soil, sediment, and even certain types of fish, making them “forever chemicals.” Plastic cups had to have stickers on them promising they were bisphenol A (BPA) free.
-
4 weeks ago | 
endocrinenews.endocrine.org | Derek Bagley
Before you reach for that arthritis supplement, take note: Over-the-counter supplements could contain surreptitious glucocorticoids, notes a new case series study published in The Journal of The Endocrine Society. The study describes 12 patients who developed Cushing syndrome (CS) and/or adrenal insufficiency (AI) after consuming commonly used supplements such as Artri King, Ardosons, and Ajo Rey — none of which disclosed glucocorticoid content on their labeling.
-
1 month ago | 
endocrinenews.endocrine.org | Derek Bagley
“Cosmic Bubble” image features cells from a thyroid cancer subtype Sriram Gubbi, MD, won the Endocrine Society’s 2025 Endocrine Images Art Competition with his microphotograph of follicular thyroid carcinoma cells titled “The Cosmic Bubble”. The art competition celebrates the beauty of endocrine science as seen through the lens of a microscope.
-
1 month ago | 
endocrinenews.endocrine.org | Derek Bagley
Each May in the U.S. is National Osteoporosis Awareness and Prevention Month which is observed to raise awareness about osteoporosis, promote prevention, and early detection. Bone health is one of the cornerstones of endocrine science and practice, so we felt that this was the perfect issue to take a look at some of the recent research focusing on bone health and potential treatment breakthroughs.
-
1 month ago | 
endocrinenews.endocrine.org | Derek Bagley
Males diagnosed with classic congenital hyperplasia (CAH) due to 21-hydroxylase deficiency require lifelong treatment, with adolescence the most challenging treatment period, notes a review article in The Journal of Clinical Endocrinology & Metabolism and a supplement sponsored by Neurocrine Biosciences, Inc., an American biopharmaceutical company that develops for neurological and endocrine-related disorders.
-
2 months ago | 
endocrinenews.endocrine.org | Glenda Fauntleroy Shaw |Derek Bagley
Barbara Kahn, MD, initially pursued medical school to understand how the human body works and to help patients with chronic illnesses. During her general medicine fellowship, her cross-over study on blood glucose and urine glucose monitoring led to invitations from U.K. researchers to tour their research institutes — a pivotal experience that revealed basic research as an alternate path to her goal of helping people with chronic illnesses live long, gratifying lives.
-
2 months ago | 
endocrinenews.endocrine.org | Derek Bagley
Last month Corcept Therapuetics Incoporated announced that the U.S. Food and Drug Administration (FDA) filed its New Drug Application (NDA) submission for the company’s proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT trial, long-term extension trial, and a Phase 2 trial in hypercortisolism.
-
2 months ago | 
endocrinenews.endocrine.org | Kelly Horvath |Derek Bagley |Mark Newman
With evidence proliferating that endocrine-disrupting chemicals (EDCs) affect thyroid hormone synthesis, transport, metabolism, and action; that gestational exposure to environmental thyroid hormone disruptors affects cognitive function; and that exposure in general increases thyroid cancer risk, one session at ENDO 2025 explores these deleterious effects and some of their proposed underlying mechanisms in detail.
